Prognostic Factors of Low-Grade Gliomas in Adults

Deacu, Mariana; Popescu, Steliana; Axelerad, Any Docu; Topliceanu, Theodor Sebastian; Aschie, Mariana; Bosoteanu, Madalina; Cozaru, Georgeta Camelia; Cretu, Ana Maria; Vodă, Raluca Ioana; Orășanu, Cristian Ionuț

doi:10.3390/curroncol29100576

Cited by 6 publications

(2 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two large randomized EORTC studies already attempted to predict the prognosis of LGGs though risk scores, which include 5 factors. A patients with low-risk prognostic score (<two factors) generally had a longer-survival than with a high-risk score(3-5 factors ) [11].…”

Section: Discussionmentioning

confidence: 89%

A gene signature predicting prognosis of patients with low- grade gliomas receiving temozolomide therapy

Wan

Deng

et al. 2023

Preprint

View full text Add to dashboard Cite

Temozolomide (TMZ) has been used as a first-line therapy against low-grade gliomas (LGGs) combined with other chemotherapy drugs. However, there has been no reliable index predicting TMZ response of patients with LGGs. In this study, we aim to investigate the relationship between gene expressions and the prognosis of TMZ therapy in LGGs. We integrated transcriptome and clinical data of 171 LGGs from the Chinese Glioma Genome Atlas (CGGA). Consensus LASSO Cox regression was used to identify 14 key genes related to different clinical outcomes under TMZ chemotherapy. We constructed and evaluated a risk score based on the 14 genes. Patients with LGGs of lower risk scores (low-risk group) generally had better survival than those LGGs of higher risk scores (high-risk group), which is independent of clinicopathological factors. High-risk patients showed activation of innate and humoral-type immunity. The prognostic contribution of the risk score was validated in an independent validation cohort of 65 patients. Besides, combined with three independent predictors (grade, IDH1 mutation status, and chr1p19q co-deletion status), we further developed a nomogram to predict the benefit from TMZ treatment in LGGs. Our results indicate that transcriptome-based index can optimize the treatment strategy for patients with LGGs under TMZ therapy.

show abstract

Section: Discussionmentioning

confidence: 89%

A gene signature predicting prognosis of patients with low- grade gliomas receiving temozolomide therapy

Wan

Deng

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…IDHmutant gliomas are further divided into oligodendroglioma and astrocytoma based on 1p/19q codeletion status [7]. It is observed from previous studies that LGG patients with 1p/19q codeletion not only have a favorable prognosis, but also are more sensitive to chemotherapy [8][9][10][11]. Aberrant expression of genes located in chromosome arms 1p and 19q has been implicated in the great clinical heterogeneity between different glioma subtypes [12,13].…”

Section: Introductionmentioning

confidence: 99%

Comparison of Low-Grade Gliomas Molecular Features and Survival by 1p/19q Codeletion in The Cancer Genome Atlas

Ma,

Su,

Tang

et al. 2023

Preprint

View full text Add to dashboard Cite

In patients with low-grade gliomas (LGG), the prognosis is significantly favorable in those with 1p/19q codeletion than in those with 1p/19q intact. Although 1p/19q codeletion has emerged as an accepted indicator for molecular typing of gliomas, numerous studies point to the need to further investigate the overall transcriptomic molecular changes associated with it. To explore the genome-wide effects of 1p/19q codeletion, we evaluated multiple omics profiles from The Cancer Genome Atlas LGG cohort. After systematic analysis, we identified a modest number of genomic features, including gene expression (n = 14), protein expression (n = 8), DNA methylation (n = 9), somatic mutation (n = 7) and copy number variation (n = 35). These features were highly corelated with 1p/19q codeletion status of patients. These features are then used to construct support vector machine classifiers and identify survival-related markers. It is helpful from this research to generate fresh insights into the alterations occurring behind the 1p/19q codeletion and to elucidate the mechanisms of LGG histological typing.

show abstract

A modified melanoma-molGPA scoring model: assessment of survival after and efficacy of different radiotherapy modalities in patients with melanoma brain metastases

Zhang

et al. 2023

Discov Onc

View full text Add to dashboard Cite

Purpose Patients with malignant melanoma brain metastases (MBMs) have poor prognoses. For MBMs, the Melanoma-molGPA is the most widely used predictive score, but its predictive value remains uncertain in patients fully treated with radiotherapy. We identified MBMs prognostic factors and modified the prognostic scoring model. Methods We retrospectively analyzed patients diagnosed with MBMs between December 2010 and November 2021 for prognostic factors influencing overall survival (OS) by univariate and multivariate analyses. Nomogram plots were based on Cox regression modeling. We evaluated overall survival (OS) using Kaplan–Meier survival curves and log-rank tests. Results The median OS (mOS) was 7.9 months. On multivariate analysis, BRAF mutation status (p < 0.001), number of brain metastases (BM) (p < 0.001), presence of liver metastases (p < 0.001), brain metastases with a midline shift (p = 0.003), Karnofsky Performance Score (p = 0.02), and lymphocyte-to-monocyte ratio (p < 0.0001) were independent OS predictors. These were incorporated into a modified risk-stratification model. Overall, whole-brain radiotherapy (WBRT) did not significantly affect mOS (mOS, 6.89 vs. 8.83 months; p = 0.07). After risk stratification using our model, WBRT resulted in no significant survival benefit in the low-risk group (mOS 10.07 vs. 13.1 months; p = 0.71) but significantly worse prognosis in the high-risk group (mOS, 2.37 vs. 6.92 months; p = 0.026). Conclusion We propose a modified model that accurately distinguishes the prognosis of patients with MBMs and guides decision-making for radiotherapy. Based on this novel model, WBRT should be cautiously selected for high-risk patients.

show abstract

Prognostic Factors of Low-Grade Gliomas in Adults

Cited by 6 publications

References 60 publications

A gene signature predicting prognosis of patients with low- grade gliomas receiving temozolomide therapy

A gene signature predicting prognosis of patients with low- grade gliomas receiving temozolomide therapy

Comparison of Low-Grade Gliomas Molecular Features and Survival by 1p/19q Codeletion in The Cancer Genome Atlas

A modified melanoma-molGPA scoring model: assessment of survival after and efficacy of different radiotherapy modalities in patients with melanoma brain metastases

Contact Info

Product

Resources

About